drugset
drugset / Trial / NCT00300027

Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies

NCT00300027 ↗

Phase 1 Terminated 50 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to define the recommended dose of BMS-582664 that could be safely combined with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) or 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimens in patients with advanced gastrointestinal malignancies and to evaluate the safety profile, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of these combinations.

Timeline

Start
2006-04
Primary completion
2006-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivanib alaninate Small molecule — —

Indications

digestive system neoplasm